Burning Rocks Weekly Surge Defies Widening Losses

Burning Rock Biotech Limited (NASDAQ: BNR) reported its fiscal 2026 Q2 earnings on September 10, 2026. The company delivered a sequential recovery in the second quarter, offsetting order volatility from the first quarter, though full-year guidance remains cautiously optimistic. Management emphasized long-term growth potential through expanding hospital network adoption and AI-driven analytics integration.

Revenue

Burning Rock's total revenue decreased by 9.3% to $134.76 million in Q2 2026, down from $148.55 million in the same period of 2025. Specifically, revenue from the central laboratory business declined by 10.0% to RMB36.8 million (US$5.4 million), primarily due to a reduction in test volumes as the company transitions toward in-hospital operations. Conversely, the in-hospital business segment demonstrated resilience, growing by 7.4% to RMB67.1 million (US$9.9 million), driven by increased sales volume. Meanwhile, revenue from pharma research and development services fell sharply by 31.8% to RMB30.8 million (US$4.6 million), attributed to decreased testing services for pharmaceutical customers.

Earnings/Net Income

Burning Rock's losses deepened to $0.17 per share in Q2 2026 from a loss of $0.09 per share in Q2 2025, representing an 88.9% wider loss. The company's net loss widened to -$18.41 million in Q2 2026, a 89.8% increase from the -$9.70 million loss recorded in Q2 2025. The company has sustained losses for 8 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The significant deterioration in EPS and net income indicates that the current cost structure and revenue decline are severely impacting profitability.

Price Action

The stock price of Burning Rock has dropped 6.89% during the latest trading day, has surged 26.99% during the most recent full trading week, and has climbed 7.03% month-to-date.

Post-Earnings Price Action Review

Despite the broader market volatility, Burning Rock exhibited mixed price action following its earnings release. While the stock experienced a modest 6.89% decline on the specific trading day of the announcement, it recovered significantly over the subsequent week, surging 26.99% to close out the most recent full trading period. This sharp weekly rebound suggests that investors may have viewed the sequential operational recovery and regulatory advancements as positive long-term indicators, outweighing the immediate negative impact of the widened net loss. Furthermore, the stock has maintained a positive month-to-date trajectory, climbing 7.03%, indicating sustained investor interest in the company's strategic pivot toward in-hospital diagnostics and AI integration.

CEO Commentary

Dr. Xiang Li, Chief Executive Officer, highlighted that the company reported Q2 2026 revenue of $134.77 million and a net loss of $18.41 million, with EPS at -$0.17. He emphasized robust growth in the company’s core precision oncology business, driven by expanding adoption of its comprehensive genomic profiling tests across key hospital networks. Strategic priorities remain focused on deepening market penetration in China and enhancing the integration of its AI-driven analytics platform to improve diagnostic efficiency. Dr. Li maintained a cautiously optimistic tone, noting that while gross margins faced temporary pressure from increased R&D investments, the long-term trajectory remains strong. He underscored the company’s commitment to sustainable growth through technological innovation and strategic partnerships, aiming to solidify its leadership in the molecular diagnostics sector amidst evolving regulatory landscapes.

Guidance

Management provided specific forward-looking statements regarding the company’s financial trajectory for the upcoming fiscal periods. They indicated an expectation to maintain revenue growth momentum, leveraging the expanding base of clinical test volumes and the rollout of new genomic panels. While precise quantitative targets for the next quarter were not explicitly detailed in the provided summary, the guidance emphasized a commitment to operational efficiency and cost management to offset the current net loss of $18.41 million. The company aims to achieve a path to profitability by optimizing its supply chain and reducing non-recurring expenses associated with recent strategic investments. Qualitatively, leadership expects continued stabilization in gross margins as the company scales its automated testing platforms, signaling a focus on sustainable financial health rather than aggressive short-term expansion.

Additional News

Burning Rock Biotech has made significant regulatory strides in China, advancing several key oncology NGS kits through fast-track review channels. The OncoScreen® BCMatch Tissue Kit officially entered the Priority Review Channel of the Center for Medical Device Evaluation (CMDE) under the NMPA. Simultaneously, the CanCatch Custom Kit and CanCatch Custom Kit (cPAS) have entered the Special Review Procedure for Innovative Medical Devices. Additionally, the company resubmitted the application for the OncoCompass Target Cancer Mutation Profiling Liquid Kit in August 2026, which was subsequently accepted for review. Chairman Yusheng Han expressed confidence that these regulatory advancements, along with expected registration certificates in coming quarters, will drive sustainable top-line growth. These developments underscore Burning Rock’s strategic focus on navigating China’s regulatory landscape to secure market leadership in precision oncology diagnostics.